Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells
about
MUC1-C oncoprotein activates ERK→C/EBPβ signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cellsIntracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle FormulationCharacterization of the MUC1-C Cytoplasmic Domain as a Cancer TargetOrigin of anti-tumor activity of the cysteine-containing GO peptides and further optimization of their cytotoxic properties.Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.MUC1-C activates BMI1 in human cancer cells.Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells.MUC1: a multifaceted oncoprotein with a key role in cancer progression.Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cellsMUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cellsMUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-κB p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells.MUC1-C activates the TAK1 inflammatory pathway in colon cancerThe MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function.Binding of Galectin-3, a β-Galactoside-binding Lectin, to MUC1 Protein Enhances Phosphorylation of Extracellular Signal-regulated Kinase 1/2 (ERK1/2) and Akt, Promoting Tumor Cell MalignancyInhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells.Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches.MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors.MUC1-C drives MYC in multiple myelomaOncogenic MUC1-C promotes tamoxifen resistance in human breast cancer.MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition.MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia.MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cellsTargeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge.MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway.MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas.MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.MUC1-C activates EZH2 expression and function in human cancer cells.MUC1-C is a target in lenalidomide resistant multiple myeloma.Death Receptor 5 Activation Is Energetically Coupled to Opening of the Transmembrane Domain Dimer.MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer.MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
P2860
Q24336566-40E51F47-8D19-4940-BDF2-E11CEA98A395Q28394194-196271A5-15D7-4434-812E-3AD8B2BAA7A5Q28547180-DE13F624-D9F9-43AD-888D-493F6A1CFC36Q29248355-2B6E4D27-0635-4109-8C28-B5E1C73249B8Q33585280-5BDC63BE-09FD-46D6-9C1A-4A5FB98C54DBQ33704573-0B76B94D-29B7-49AB-87EE-8D51C5A0587FQ33757061-E5BFEEC7-9393-4F7B-AF4B-59D824B90C73Q33880143-2AD43869-BEB3-4603-B11C-018710F4CCD5Q34449722-B5B5DF56-A751-4DD8-981F-6BF224982B75Q34619148-11F117E9-59BA-4668-A0BB-8150BBA94F96Q34737810-A1BCEEE2-B819-4A51-B8A0-54EA83D806F5Q35931767-B8F8CBBE-96B0-459D-A6DC-8B4C872104A4Q36033113-D889461E-047A-44CB-AFBB-527F41745F1FQ36283550-93517DC1-86FE-4D43-8E1A-886FA6CB3BDAQ36608702-3145B568-5DAB-4B5A-AE23-F5F4B81B12ADQ36693297-383E5E6F-6F89-4619-A671-87D6ECB946A1Q36753508-E391A2AB-9C81-451A-B6BA-16EEE0DBF295Q36928457-85CD7BE4-D6B3-4396-942E-6F4B75988F29Q36942036-A5890603-759D-4C5D-966F-FC4615E95E41Q37038731-594562BB-0D93-4935-BD91-10988264D6AAQ37198652-E643E713-FE1D-4121-ADF7-33E70D384A47Q37457356-7CB7D386-6966-4605-884D-DF479DA13B52Q37535249-4C9D7D90-1306-4271-9161-BB34FBFE407EQ37565022-1DE1A373-A053-4959-A9B3-6026B15ED160Q38091088-D32C33A4-CC2F-4DB3-A212-F813A5ACDF4EQ38744303-C96F34EA-87A6-4581-9725-CFF90B219849Q39182659-7772C516-81B4-4A66-AA7B-68E259FD9837Q41008660-F4EB8A0A-BE97-4D6A-BD6B-196B479ED1AFQ41286875-B125B470-1485-47DE-AE62-05FE94801EDDQ46345708-FE34DB8A-0401-4352-94F2-F8E5E9D481E1Q47877355-E5F669DF-6107-427C-81A0-981B8879BBFDQ47951334-C9A4A7FE-D1E6-499D-90E4-EE600A652413Q52742033-1AED29DE-D9E3-4B2E-9363-446F47B0A4F2
P2860
Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Targeting cysteine-mediated di ...... human cancer cells
@ast
Targeting cysteine-mediated di ...... human cancer cells
@en
type
label
Targeting cysteine-mediated di ...... human cancer cells
@ast
Targeting cysteine-mediated di ...... human cancer cells
@en
prefLabel
Targeting cysteine-mediated di ...... human cancer cells
@ast
Targeting cysteine-mediated di ...... human cancer cells
@en
P2093
P2860
P356
P1476
Targeting cysteine-mediated di ...... human cancer cells
@en
P2093
Deepak Raina
Donald Kufe
Govind Panchamoorthy
Hasan Rajabi
Rehan Ahmad
Surender Kharbanda
P2860
P304
P356
10.3892/IJO.2011.1308
P577
2011-12-20T00:00:00Z